IQVIA Holdings Inc. (IQV) EBITDA Margin: 21.24%
Is IQVIA Holdings Inc.’s EBITDA margin high or low?
IQVIA Holdings Inc.'s EBITDA margin of 21.24% is in line with its 5-year average of 20.63%, near the high end of its 5-year range (18.28%–22.41%).
The EBITDA margin for IQVIA Holdings Inc. (IQV) is 21.24% as of Tuesday, June 9, 2026. It is below its 12-month average by 2.68% (21.82%).
IQV EBITDA Margin Chart
IQV Average EBITDA Margin Chart
IQV Current vs Average EBITDA Margin Chart
IQV EBITDA Margin Metrics
EBITDA MARGIN
21.24%
EBITDA MARGIN AVG TTM
21.82%
EBITDA MARGIN AVG 3Y
21.39%
EBITDA MARGIN AVG 5Y
20.63%
EBITDA MARGIN AVG 10Y
18.44%
EBITDA MARGIN AVG 15Y
16.13%
EBITDA MARGIN AVG 20Y
16.13%
CURRENT VS TTM AVG
-2.68%
CURRENT VS 3Y AVG
-0.71%
CURRENT VS 5Y AVG
+2.95%
CURRENT VS 10Y AVG
+15.21%
CURRENT VS 15Y AVG
+31.72%
CURRENT VS 20Y AVG
+31.72%
IQV Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | — | 21.24% | 21.82% | 21.39% | 20.63% |
| DexCom, Inc. (DXCM) | $30.17B | 24.96% | 24.20% | 23.29% | 21.36% |
| Centene Corporation (CNC) | $32.69B | -2.64% | 0.58% | 1.90% | 2.49% |
| Biogen Inc. (BIIB) | $29.39B | 31.60% | 31.28% | 30.38% | 32.54% |
| Zoetis Inc. (ZTS) | $34.46B | 42.98% | 42.41% | 42.38% | 41.76% |
| Veeva Systems Inc. (VEEV) | $27.37B | 28.68% | 27.64% | 24.37% | 25.68% |
| Waters Corporation (WAT) | $24.19B | 31.97% | 33.50% | 33.77% | 33.93% |
| Agilent Technologies, Inc. (A) | $38.26B | 26.41% | 27.60% | 26.98% | 26.47% |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 30.67% | 31.14% | 31.31% | 30.59% |
| BioNTech SE (BNTX) | $21.87B | -9.29% | -11.31% | 22.27% | 24.39% |
Margin Comparison
Gross Margin
26.3%
EBITDA Margin
21.2%
Operating Margin
14.0%
Net Margin
8.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
IQVIA Holdings Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IQVIA Holdings Inc. EBITDA Margin FAQ
- What is the EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The EBITDA margin for IQV stock is 21.24%.
- Is IQVIA Holdings Inc.'s EBITDA margin high or low?
- IQVIA Holdings Inc.'s EBITDA margin of 21.24% is in line with its 5-year average of 20.63%, near the high end of its 5-year range (18.28%–22.41%).
- What is the TTM average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The TTM average EBITDA margin for IQV stock is 21.82%.
- What is the 3Y average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The 3Y average EBITDA margin for IQV stock is 21.39%.
- What is the 5Y average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The 5Y average EBITDA margin for IQV stock is 20.63%.
- What is the 10Y average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The 10Y average EBITDA margin for IQV stock is 18.44%.
- What is the 15Y average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The 15Y average EBITDA margin for IQV stock is 16.13%.
- What is the 20Y average EBITDA margin for IQVIA Holdings Inc. (IQV)?
- The 20Y average EBITDA margin for IQV stock is 16.13%.
IQVIA Holdings Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 21.24% |
| 2024-12-31 | 22.41% |
| 2023-12-31 | 21.73% |
| 2022-12-31 | 20.19% |
| 2021-12-31 | 19.94% |
| 2020-12-31 | 18.28% |
| 2019-12-31 | 18.05% |
| 2018-12-31 | 18.08% |
| 2017-12-31 | 17.02% |
| 2016-12-31 | 12.46% |
| 2015-12-31 | 13.39% |
| 2014-12-31 | 13.24% |
| 2013-12-31 | 10.87% |
| 2012-12-31 | 10.28% |
| 2011-12-31 | 8.91% |
| 2010-12-31 | 11.91% |
Related Metrics
About IQVIA Holdings Inc.
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Ari Bousbib